Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $117.9 million.

  • TScan Therapeutics' Total Non-Current Liabilities fell 73.07% to $117.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.9 million, marking a year-over-year decrease of 73.07%. This contributed to the annual value of $130.0 million for FY2024, which is N/A changed from last year.
  • TScan Therapeutics' Total Non-Current Liabilities amounted to $117.9 million in Q3 2025, which was down 73.07% from $121.7 million recorded in Q2 2025.
  • TScan Therapeutics' 5-year Total Non-Current Liabilities high stood at $130.0 million for Q4 2024, and its period low was $20.7 million during Q2 2022.
  • Over the past 5 years, TScan Therapeutics' median Total Non-Current Liabilities value was $99.6 million (recorded in 2022), while the average stood at $82.3 million.
  • Per our database at Business Quant, TScan Therapeutics' Total Non-Current Liabilities plummeted by 3199.29% in 2022 and then soared by 51111.0% in 2023.
  • TScan Therapeutics' Total Non-Current Liabilities (Quarter) stood at $27.2 million in 2021, then soared by 265.78% to $99.6 million in 2022, then grew by 22.89% to $122.4 million in 2023, then grew by 6.21% to $130.0 million in 2024, then dropped by 9.3% to $117.9 million in 2025.
  • Its last three reported values are $117.9 million in Q3 2025, $121.7 million for Q2 2025, and $122.4 million during Q1 2025.